Could drugs for type 2 diabetes help those with type 1?
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin, have been game changers in the treatment of type 2 diabetes, but their potential for closing the mortality gap in type 1 diabetes has been a regulatory minefield. The metabolic benefits of SGLT2 inhibition in type 1 diabetes were demonstrated across three clinical trial programs, resulting in weight loss and improved glycated hemoglobin levels, without increased hypoglycemia risk.